Nutritional Implications of Methotrexate in Osteoarthritis: A Systematic Review and Meta-Analysis

Read full text Summarise with VIRAT
Authors: Saud Nayef Aldanyowi, Abdulsalam Mohammed Aleid, Yousef Khalaf A Alghamdi, Hasan Ali Abdullah Alaidarous, Zainab Mohammed Aleid
Cited by: 0
References: 22

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

INTRODUCTION: Osteoarthritis (OA) is a prevalent degenerative joint condition with limited treatment options targeting disease modification. Methotrexate (MTX), widely used in rheumatoid arthritis for its anti-inflammatory properties, may offer similar benefits in OA. However, its effectiveness and nutritional implications in OA remain uncertain. METHODS: We conducted a systematic review and meta-analysis following PRISMA guidelines, registered in PROSPERO (CRD42024592121). We searched PubMed, Web of Science, OVID, and Cochrane Central up to August 2024 for randomized controlled trials comparing MTX with placebo in OA patients. Risk of bias was assessed using the Cochrane RoB 2 tool, and data were synthesized using Review Manager (RevMan) 5.4. RESULTS: Four trials involving 416 participants were included. MTX significantly reduced pain at 3 months (SMD = -0.33, p = 0.006) and 6 months (SMD = -0.53, p = 0.0004), and stiffness at 6 months (SMD = -0.48, p < 0.0001). No significant improvement in physical function was found in the primary analysis (SMD = -1.07, p = 0.09), but sensitivity analysis excluding one high-risk study showed a modest benefit (SMD = -0.34, p = 0.01). Adverse events were consistent with low-dose MTX use. No study reported folate levels, but folate supplementation is recommended to mitigate MTX-related nutritional risks. DISCUSSION: MTX appears to offer symptom relief in OA and may enhance function in select patients. Nutritional monitoring, particularly folate status, should accompany MTX therapy. CONCLUSION: MTX shows promise as an adjunct therapy for OA. Larger, long-term trials incorporating nutritional parameters are warranted.

Fields of Study & Subjects

Osteoarthritis Treatment and Mechanisms Rheumatoid Arthritis Research and Therapies Musculoskeletal pain and rehabilitation

Publication details

Journal / source
Reviews on Recent Clinical Trials
Volume
21
Issue
5
Pages
e15748871406171–e15748871406171
Publication date
20 March 2026
Language
EN